Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 6/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25819126 | 0.87 | L3MBTL1 (0.47) | L3MBTL1MAPTSQORLMNACNR1 | |
| SCHEMBL26043793 | 0.86 | MAPT (0.47) | L3MBTL1MAPTRAB9ASMN1; SMN2SQOR | |
| SCHEMBL26043794 | 0.86 | L3MBTL1 (0.46) | L3MBTL1SQORCNR1PDE5A | |
| SCHEMBL25935014 | 0.85 | GABRG2 (0.49) | MEN1KMT2AL3MBTL1SQORCNR1 | |
| SCHEMBL25819183 | 0.85 | AR (0.44) | MEN1KMT2AL3MBTL1SQORCNR1 | |
| SCHEMBL23983264 | 0.84 | GRM5 (0.43) | L3MBTL1SQORLMNACNR1MCL1 | |
| SCHEMBL29681838 | 0.84 | GRM5 (0.43) | L3MBTL1SQORLMNACNR1MCL1 | |
| SCHEMBL25819597 | 0.82 | L3MBTL1 (0.42) | MEN1KMT2AL3MBTL1SQORCNR1 | |
| Formic Acid SCHEMBL29197680 | 0.81 | MCL1 (0.42) | SQORLMNACNR1MCL1 | |
| SCHEMBL25819197 | 0.80 | L3MBTL1 (0.44) | MEN1KMT2AL3MBTL1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | MEN1 3601/4885KMT2A 2176/4885L3MBTL1 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.